Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16

Benzinga Newsdesk www.benzinga.com Positive 68.8%

Neg 0% Neu 0% Pos 68.8%

Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $15 to $16.